Objective To evaluate osteoporosis in asthmatic patients. Methods Bone mineral density (BMD)was measured using three different methods, namely computed X-ray densitometry (CXD), digital image processing (DIP), and dual energy X-ray absorptiometry (DXA). The BMDdata were standardized using the sex-and age-matchedmean value of BMD.
Introduction
Inhaled corticosteroids (ICS) are currently the first-line treatment for bronchial asthma. The systemic effects of ICS, such as suppression of the hypothalamic-pituitary-adrenal axis, are generally less than the effects of oral corticosteroids (OCS) (1, 2) . Anevidence-based approach to the analysis of systemic activity and the safety of ICS is essential to allow appropriate risk-benefit decisions to be made for individual patients with bronchial asthma. OCSare well knownto have adverse effects on bone mineral density (BMD), and to accelerate bone loss and hence double the risk of fracture in patients taking more than 7.5 mg of prednisolone daily (3) . Osteoporosis is a fracture syndromethat results from low BMD. BMD is a major determinant of the fracture risk in patients with corticosteroid (CS)-induced osteoporosis, as the fracture risk increases progressively when the BMDfalls below a specific fracture threshold(4).
Several studies have examined the effects of ICS on BMD in asthmatic patients, with conflicting results (5, 6) . Fluticasone propionate (FP, 500 jig/day) has been shown not to cause any adverse effects on BMD in mild and moderate adult asthmatics after a one-year treatment period (5) . In contrast, there is someconcern that prolonged treatment with high doses of ICS reduces bone mass in prepubertal asthmatic children (6) . It appears that high doses (more than 400 jig/day in children and more than 800 |ig/day in adults) of beclomethasone dipropionate (BDP) may affect bone metabolism and BMD (7) . Several techniques are available for measuring BMD. Among these, dual energy X-ray absorptiometry (DXA) is the most reliable, and usually the lumbar spine is the target (8) . However, this methodrequires a special device and evaluation at the lumbar spine is time consuming. Wemeasured BMDin adult asthmatic patients using three different methods, namely DXA, computed X-ray densitometry (CXD), and digital image processing (DIP). BMDwas measured at the distal edge of the radius in DXA, as this was more convenient than the lumbar spine and not influenced by lumbar spinal deformities. The second metacarpal bone was also utilized to measure BMDby CXDor DIP. These methods are convenient for hospital outpatient departments.
Two kinds ofICS, BDPand FP, have been used in Japan. The systemic effects of FP, such as growth and bone turnover, appear to be smaller than those of BDP(9-1 1). Here, we investigated whether BMDin adult patients with persistent bronchial asthma is lower than the norm. Wealso examinedthe change in BMDin patients receiving FP or FP plus OCS. 
Materials and Methods

S ubjec ts
Measuring BMD
The BMDof 32 patients was measured at the distal edge of the radius by DXAusing a QDR-4500SL densitometer (Holgic Inc., Waltham, MA, USA). The BMDof 96 patients was measured at the second matacarpal bone by CXD(66 patients) or DIP (30 patients). The measuring value of BMDwas standardized and expressed as Z-score. Z-score was calculated by the following formula. Z-score= (P-Mam)/SDam, P: measuring value in the patient. Mam: the meanvalue of the samesex and the same aged people measured by the same method, SDam: the standard deviation (SD) of the mean value of the same sex and the same aged people measured by the same method.
Sta tis tics
For continuous variables, differences between groups were compared using analysis of variance (ANOVA)and post hoc multiple comparisons were performed using Tukey-Kramer's method. Twoindependent groups were compared using Wilcoxonsigned-rank test or the paired t-test.
Results
BMDin patients with persistent bronchia/ asthma as 12 months (Fig. 2C) . Forty-four patients consisted of 17 males and 27 females. The standardized BMDin men as well as womendid not change significantly during the 12 months (Fig. 2D) . However, the BMDin patients using both FP and OCS significantly decreased during the 6 months. The daily dose of FP in these patients was 590±200 |ig (mean±SD, n=20) (Fig. 2E) . Twenty patients using both FP and OCS consisted of 9 males and ll females. Standardized BMDof menwas not different from that of women (Fig. 2F) . The daily dose of OCS in these patients was 5.9±3.4 mg (mean±SD) as prednisolone.
BMDin older patients with persistent bronchial asthma Wedivided all patients into two groups according to age.
The standardized BMDexpressed as Z-score was significantly lower in patients 60 years and over (-0.71±1.10, mean±SD, n=58) than patients under 60 (-0.3011.21, n=70) (Fig. 3A) . Body weight of the patients was not significantly different between these two groups, and there was no significant difference of the standardized BMDbetween men and women (Fig.  3B) . Furthermore, we investigated the effect of CS therapy on BMDin these older patients, by measuring BMDtwice at intervals of 6 months (n=45, 16 males and 29 females). Fourteen patients of 45 used both ICS and OCS. The remaining 31 patients used only ICS. The BMDin the patients 60 years and over was significantly lower after the 6-month treatment (Fig.   3C ). There was no significant difference of the standardized BMD between menand womenin these older patients (Fig.  3D) . However, the BMDin 26 patients treated with FP but not OCSdid not decrease significantly (Fig. 3E) , suggesting that the decrease in BMDin these older patients is due to OCS. In contrast, the BMDin the patients under 60 years did not decrease after treatment (Fig. 3C) .
Comparison of the three methods used to measure BMD As we measured BMDusing three different methods, we investigated the effects of FP on BMDin each group (CXD, DIP, DXA 
Discussion
Osteoporosis is a serious health problem associated with pain, loss of independence, and increased mortality. Each vertebral compression fracture has been estimated to cause a 10% decrement in FVCin normal subjects (12) . Therefore, the effect of osteoporosis on pulmonary function in bronchial asthma is likely substantial. Patients with persistent bronchial asthma usually receive chronic treatment with ICS, while some patients require OCS with ICS.
Weevaluated BMDin 128 patients with persistent bronchial asthma. The sex-and age-adjusted BMD(Z-score) in these patients was significantly lower than the norm. Whenwe divided these patients into two groups according to continuous use of OCSin the past 2 years, the BMDof patients treated with OCSwas significantly lower than that of patients treated without OCS. These results suggest that decreased BMD in asthmatic patients is primarily due to the use of OCS. However, wecannot eliminate the possibility that the severity of the asthma itself may cause a decrease in BMD. CS are the most effective anti-inflammatory medications currently available for the treatment of asthma, although the mechanismsby which these drugs act to relieve asthma symptoms are not completely understood. ICS are the preferred route of administration for long-term maintenance therapy, as they produce a significantly lower incidence of adverse reactions than OCS (13) . The local adverse effects of ICS include oropharyngeal candidiasis, hoarseness, and cough due to irritation of the upper airways (14) . Although patients requiring high doses of ICS for asthma control may be at long-term risk of bone loss, the loss is likely to be to a muchsmaller extent than with maintenance OCStherapy (13) . Furthermore, many studies support the safety of ICS on BMDin asthmatic patients (15, 16) . However, because most studies have excluded a priori individuals older than 50 or postmenopausal womento avoid the confounding influences of age and menopausal status on bone loss, the relative safety of ICS therapy in these susceptible populations remains unknown. In our investigation, BMDstandardized by the sex-and age-matched mean value of BMD(Z-score) in older patients was significantly lower than the standardized BMDin patients under 60 years old. Moreover, BMDin these older patients decreased significantly after the 6-month treatment. The BMDin humans decreases with increasing age, with decrease being particularly marked in postmenopausal women. Arecent study has demonstrated that ICS treatments decrease the BMDin postmenopausal women (17) . Thus, BMDin older asthmatics, especially women, should be measured regularly and osteoporosis in these patients needs to be treated adequately.
In our investigation, BMDdid not change in patients treated with FP alone over 6 or 12 months. Surprisingly, the BMDin patients treated with both FP and OCS significantly decreased during the 6-month treatment. The BMDin older patients also decreased, presumably due to OCStherapy. In the patients with severe persistent bronchial asthma, continuous administration of OCSis sometimesrequired together with a high dose of ICS to control their symptoms. Weshould be very careful with the decrease of BMDin these patients even at a low OCSdose. Weused three different methods to investigate BMDin this study for hospital reasons. Wethink it is better to use the same method and utilize cancellous bone in order to analyze the effect of CS on BMDmore accurately. In summary, the standard FP dose (200-400 jig/day) does not affect the BMDin patients with mild or moderate persistent asthma. However, combination therapy of FP (400-800 jLtg/day) and OCSin patients with severe persistent asthma may affect the BMDin the short term. Therefore, patients with severe persistent asthma receiving both ICS and OCSshould be considered for bone densitometry screening. In future studies, it will be important to investigate whether OCS,such as a low dose of prednisolone, may affect the BMDin patients with severe persistent asthmain the short term or not.
